This study is evaluating the safety and potential benefits of an investigational natural killer (NK) cell therapy called AlloNK® when combined with rituximab.
The therapy is being studied in individuals with relapsing forms of:
This study is evaluating the safety and potential benefits of an investigational natural killer (NK) cell therapy called AlloNK® when combined with rituximab. The therapy is being studied in individuals with relapsing forms of:
.png){kind=icon}
Open to adults across select U.S. clinical research centers.
For people 18+ diagnosed with IIM, SSc, RA, or Sjögren’s Disease who haven’t responded to standard treatment.
Participants will receive an investigational NK cell therapy (AlloNK®) and rituximab, with clinic visits and health assessments.
.png){kind=icon}
Participants may receive compensation for their time and participation.
Additional criteria apply.
A screening visit will determine final eligibility.
.png)
This research study is evaluating a potential new immune cell therapy (AlloNK®) given with rituximab in adults with certain autoimmune diseases that haven’t responded well to standard treatments.
The study is enrolling participants with one of the following diagnoses:
- Idiopathic Inflammatory Myopathies (IIM)
- Systemic Sclerosis (SSc)
- Rheumatoid Arthritis (RA)
- Sjögren’s Disease (SjD)
Some medications may need to be paused before or during the study. The study team will review your current treatments and explain any changes before enrollment.
Yes, eligible participants may receive compensation. The exact amount will be shared during the informed consent process.
